Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 Biochemical and morphological consequences of human a-synuclein expression in a mouse a-synuclein null background. Eur J Neurosci, 33:642-656, 2011
2. 2009 The parkinson’s disease kinase, LRRK2, autophosphorylates its ROC/GTPase domain at multiple sites BBRC, 389:449-454, 2009
3. 2008 Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 {[2-(4-Benzo[1,3]dioxol-5-yl-2-tert-butylphenoxy)ethyl]-methylamino)-acetic acid indicate a preferential action in the brain stem and cerebellar vs. prefrontal cortical brain areas Neuropharmacol, 55:743-754, 2008
4. 2008 Animal Models of Parkinson’s Disease to Aid Drug Discovery and Development In: Animal and Translational Models for CNS Drug Discovery, Vol. 2 Neurological Disorders, Robert McArthur and Franco Borsini (eds), Academic Press
5. 2007 Differential loss of presynaptic dopaminergic markers in the basal ganglia of MPTP-treated squirrel monkeys Cell Transplantation, 16:229-44, 2007
6. 2006 Neuroreplacement, growth factor and small molecule neurotrophic approaches for treating Parkinson’s Disease International Rev Neurobiol, 77: 179-217, 2006
7. 2006 Pharmacological Characterization of cGMP Regulation by the Bisarylpropylsulfonamide Class of Positive, Allosteric Modulators of AMPA Receptors J. Pharmacol. Exp. Ther., 319:293-298, 2006
8. 2006 Evaluation of white matter integrity in ex-vivo brains of amyloid plaque-bearing APPsw transgenic mice using diffusion tensor MRI. Exp. Neurol., 199:408-415, 2006
9. 2005 Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer’s disease using magnetic resonance diffusion tensor imaging. Experimental Neurology, 191:77-85, 2005
10. 2005 Developing therapeutics for schizophrenia and other psychotic disorders NeuroRx. 2:579-89
11. 2005 Expression of GAD65 and GAD67 immunoreactivity in MPTP lesioned monkeys treated with or without L-DOPA Neurobiology of Disease, 20:347-59, 2005
12. 2004 Differential regulation of behavioral, genomic and neuroendocrine responses by CRF infusions in rats. Pharmacology, Biochemistry and Behavior, 77: 447-455, 2004
13. 2004 Effectiveness of the Selective D4 Antagonist Sonepiprazole in Schizophrenia: A Placebo-Controlled Trial. Biol. Psychiatry, 55: 445-51, 2004
14. 2004 Lack of specific A(1-42) suppression by NSAIDs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther. 312:399-406, 2004
15. 2004 Studies of A-beta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) J. Pharmacol. Exp. Ther. 309: 49-55, 2004
16. 2003 The -secretase inhibitor, DAPT, reduces A levels in vivo in the CSF of young (non plaque-bearing) and old (plaque-bearing) Tg2576 mice. Pharmacol. Exp. Ther., 305:864-871, 2003
17. 2003 Activations of the Serotonin 5-HT2C receptor within the basolateral amygdala induces innate fear-like responses in an open-field environment Brain Research, 993:1-9, 2003
18. 2003 Deficiency of Nicastrin abolishes gamma-cleavage of amyloid precursor protein and Notch J. Biol. Chem., 278: 33445-9, 2003
19. 2003 Early Onset of Hippocampal-specific Decreases in Dendritic Spine Density in Transgenic Mice Over-Expressing Mutant APP Neurobiology of Disease, 13:246-53, 2003
20. 2003 Rapid habituation of hippocampal serotonin and norepinephrine release and anxiety-related behaviors, but not plasma corticosterone levels, to repeated footshock stress in rats Pharmacology, Biochemistry and Behavior, 74: 609-616, 2003
21. 2000 The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys Neuropsychopharmacology 23: 405-410, 2000
22. 1999 Increased levels of proneurotensin/neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride Neuropsychopharmacology, 21: 304-311, 1999
23. 1998 The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular changes J. Pharmacol. Exp. Ther., 286:497-508, 1998.
24. 1998 Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats Mol. Brain Research, 61: 39-50, 1998
25. 1997 Psychostimulants and neuropeptide response Adv. Pharmacology, 42: 1014-1016
26. 1997 EEDQ reduces the striatal neurotensin mRNA response to haloperidol Peptides, 18: 527-535, 1997.
27. 1996 Differential distribution of GABA-1, 2, 3, 5 2+3 immunoreactivity in the infralimbic region of the rat prefrontal cortex; a site for the efficacy of atypical antipsychotic drugs Neuroscience Letters, 210: 213-217, 1996.
28. 1996 Immediate Early gene Induction by Antipsychotic Drugs: Role of D2, D3 and D4 receptors In: Pharmacological Regulation of Gene Expression in the CNS, Ed. K.M. Merchant, CRC Press, pp 25-50
29. 1996 Evans, Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: Role of dopamine D2 and D3 receptors Cerebral Cortex, 6: 561-570, 1996
30. 1996 Pharmacological characterization of U-101387, A dopamine D4 receptor selective antagonist. J. Pharmacol. Exp. Ther., 279:1392-1403, 1996.
31. 1995 The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse Drug and Alcohol Dependence, 37: 107-110, 1995
32. 1995 Muscimol administration attenuates haloperidol-induced acute increases in neurotensin mRNA expression in the caudate-putamen but not nucleus accumbens Brain Research., 691: 9-17, 1995.
33. 1994 Neurotensin and c-fos mRNA are coexpressed in rat neostriatal neurons following acute haloperidol Molecular Brain Research, 23: 271-277, 1994
34. 1994 c-fos antisense oligonucleotide attenuates haloperidol-induced neurotensin mRNA expression in the dorsal striatum of the rat Mol. Cell. Neurosci., 5: 336-344, 1994
35. 1994 Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos gene expression in striatal subregions J. Pharmacol. Exp. Ther., 271: 460-471, 1994
36. 1994 Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum following acute methamphetamine: comparison with acute haloperidol effects J. Pharmacol. and Exp. Ther., 269: 806-812
37. 1993 Differential loss of dopamine D2 receptor mRNA isoforms during aging in Fischer-344 rats Neuroscience Letters, 154: 163-167, 1993
38. 1993 Differential induction of neurotensin and c-fos gene expression induced by typical versus atypical antipsychotics Proceedings Natl. Acad. Sci., 90: 3447-3451, 1993.
39. 1993 Blunting of the neurotensin mRNA response to haloperidol in the striatum of aging rats: Possible relationship to decline in dopamine D2 receptor expression Brain Research, 616: 105-113, 1993
40. 1992 BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in rat striatum Mol. Brain Research, 12: 279-284, 1992.
41. 1992 Distinct 5-HT1B and 5-HT1D Serotonin receptors in rat: Structural and pharmacological comparison of the two cloned receptors J. Molecular and Cellular Neurosci., 3: 578-587
42. 1992 Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum J. Neurosci., 12: 652-653, 1992
43. 1992 Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse: involvement of dopaminergic mechanisms Ann. N.Y. Acad. Sci., 668: 165-172
44. 1992 Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs Ann. N.Y. Acad. Sci., 668: 54-69
45. 1991 Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain Brain Research, 540: 311-314, 1991
46. 1991 Distinct patterns for the distribution of mRNA for the calmodulin-sensitive adenylate cyclase in rat brain: expression in areas associated with learning and memory Neuron, 6, 431-443, 1991.
47. 1990 Neurotensin-dopamine interactions in the substantia nigra of the rat brain J. Pharmacol. Exp. Ther., 255: 775-780, 1990
48. 1989 Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems in the rat brain Brain Research, 500: 21-29, 1989
49. 1989 Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems in the neostriatum and the nucleus accumbens Eur. J. Pharmacol., 160: 409-412
50. 1988 Effects of amphetamine analogs on CNS neuropeptide systems NIDA Research Monograph, 1988
51. 1988 Characterization of methamphetamine effects on striatal-nigral dynorphin system Eur. J. Pharmacol., 155: 11-18, 1988
52. 1988 Changes in the limbic neurotensin systems induced by dopaminergic drugs Eur. J. Pharmacol., 153: 1-9, 1988
53. 1987 Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of the rat Neuropharmacol., 26: 1677-1683
54. 1987 Effects of methamphetamine on neurotensin concentrations in rat brain J. Pharmacol. Exp. Ther., 241: 443-447
55. 1987 Effects of amphetamine analogues on neurotensin concentrations in rat brain European J. Pharmacol., 138: 151-154
56. 1987 Effects of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) isomers on the central serotonergic, dopaminergic and nigral neurotensin systems of the rat J. Pharmacol. Exp. Ther. 244: 977-982, 1987.
57. 1987 Characterization of dopaminergic influence on striatal-nigral neurotensin systems Brain Research, 422: 200-203, 1987
58. 1987 Methamphetamine-induced changes in striatal-nigral dynorphin system: role of D-1 and D-2 receptors Eur. J. Pharmacol., 144: 245-246
59. 1986 Comparison of responses by striatonigral substance P and neurokinin A systems to methamphetamine treatment Peptides, 983-987, 1986


Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.